Stay updated with breaking news from Dose Escalation Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activity Across Three Key...
Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation...
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable...
Data demonstrates potential for less frequent drug administrationTTI-0102 was well tolerated with no Serious Adverse Events reportedSupports EU and US regulatory submissions for human efficacy trials
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy ... | May 16, 2022